{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Interstitial+Lung+Disease+in+Patients+With+Rheumatoid+Arthritis", "query": { "condition": "Interstitial Lung Disease in Patients With Rheumatoid Arthritis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 7, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T04:05:31.255Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05855109", "title": "Developing a Screening Tool for Interstitial Lung Disease in People With Rheumatoid Arthritis Using Risk Factors", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Arthritis, Rheumatoid", "Lung Diseases, Interstitial" ], "interventions": [], "intervention_types": [], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1304, "start_date": "2023-11-27", "completion_date": "2025-06-26", "has_results": false, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 5, "location_summary": "Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 2 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT05855109" }, { "nct_id": "NCT00001885", "title": "Identification of Genes Associated With Lung Disease in Patients With Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Healthy", "Pulmonary Fibrosis", "Rheumatoid Arthritis" ], "interventions": [], "intervention_types": [], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 400, "start_date": "1999-03-21", "completion_date": "2007-12-28", "has_results": false, "last_update_posted_date": "2017-07-02", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00001885" }, { "nct_id": "NCT06329401", "title": "A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Fibrosis", "Progressive Pulmonary Fibrosis", "Pulmonary Fibrosis Secondary to Systemic Sclerosis", "Pulmonary Fibrosis, Interstitial Lung Disease", "Interstitial Lung Disease", "Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)", "Interstitial Lung Disease in Patients With Rheumatoid Arthritis", "Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere", "Hypersensitivity Pneumonitis", "Interstitial Lung Disease With Systemic Sclerosis" ], "interventions": [ { "name": "AP01", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Avalyn Pharma Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 375, "start_date": "2024-04-03", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-04-06", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 45 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06329401" }, { "nct_id": "NCT00006055", "title": "Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Purpura, Schoenlein-Henoch", "Graft Versus Host Disease", "Anemia, Hemolytic, Autoimmune", "Rheumatoid Arthritis", "Churg-Strauss Syndrome", "Hypersensitivity Vasculitis", "Wegener's Granulomatosis", "Systemic Lupus Erythematosus", "Giant Cell Arteritis", "Pure Red Cell Aplasia", "Juvenile Rheumatoid Arthritis", "Polyarteritis Nodosa", "Autoimmune Thrombocytopenic Purpura", "Takayasu Arteritis" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "filgrastim", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "Autologous Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Fairview University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "55 Years", "sex": "ALL", "summary": "1 Year to 55 Years" }, "enrollment_count": 10, "start_date": "2000-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-06-24", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006055" }, { "nct_id": "NCT07217093", "title": "Teleconsultation Approach to CTD-ILD Care Delivery in Rural UnderServed CommuniTies (TRUST Initiative)", "overall_status": "NOT_YET_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Interstitial Lung Disease Due to Systemic Disease (Disorder)", "Interstitial Lung Disease in Patients With Rheumatoid Arthritis", "Interstitial Lung Disease Due to Systemic Disease" ], "interventions": [], "intervention_types": [], "sponsor": "St. Lawrence Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2025-11", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-10-15", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 1, "location_summary": "Potsdam, New York", "locations": [ { "city": "Potsdam", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217093" }, { "nct_id": "NCT02808871", "title": "Phase ll Study of Pirfenidone in Patients With RAILD (TRAIL1)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis Interstitial Lung Disease" ], "interventions": [ { "name": "Pirfenidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Brigham and Women's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 123, "start_date": "2017-04-07", "completion_date": "2021-04-07", "has_results": true, "last_update_posted_date": "2022-08-16", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 13, "location_summary": "Birmingham, Alabama • San Francisco, California • Denver, Colorado + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02808871" }, { "nct_id": "NCT07138898", "title": "Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatic Disease" ], "interventions": [ { "name": "Methotrexate", "type": "DRUG" }, { "name": "Sulfasalazine", "type": "DRUG" }, { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Leflunomide", "type": "DRUG" }, { "name": "Azathioprine", "type": "DRUG" }, { "name": "Mycophenolate", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Etanercept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Golimumab", "type": "DRUG" }, { "name": "Certolizumab", "type": "DRUG" }, { "name": "Infliximab", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" }, { "name": "Belimumab", "type": "BIOLOGICAL" }, { "name": "Tocilizumab", "type": "BIOLOGICAL" }, { "name": "Anakinra", "type": "BIOLOGICAL" }, { "name": "Canakinumab", "type": "BIOLOGICAL" }, { "name": "Abatacept", "type": "BIOLOGICAL" }, { "name": "Secukinumab", "type": "BIOLOGICAL" }, { "name": "Ixekizumab", "type": "BIOLOGICAL" }, { "name": "Bimekizumab", "type": "BIOLOGICAL" }, { "name": "Ustekinumab", "type": "BIOLOGICAL" }, { "name": "Guselkumab", "type": "BIOLOGICAL" }, { "name": "Risankizumab", "type": "BIOLOGICAL" }, { "name": "Tofacitinib", "type": "DRUG" }, { "name": "Upadacitinib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "NYU Langone Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2025-09", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2025-08-24", "last_synced_at": "2026-05-22T04:05:31.255Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07138898" } ] }